Advances in technology have enabled monoclonal antibodies to be produced which bind to specific antigens associated with disease processes. By targeting these antigens the antibodies can destroy or alter the function of cells which express the target. They may also bind and thereby inhibit pro-inflammatory cytokines such as tumour necrosis factor. In addition to cancer treatment, monoclonal antibodies may be useful in diseases with an immune component such as rheumatoid arthritis and psoriasis. Monoclonal antibodies can have serious adverse reactions such as severe allergy and infection.
Introduction
The use of monoclonal antibodies in clinical medicine stems from their ability to modulate the natural course of disease by targeting critical pathogenic molecules. As cancer cells have particular surface antigens, they are suitable targets for therapy. 1 Monoclonal antibodies are now finding roles in many non-malignant diseases such as inflammatory joint, skin and bowel diseases, organ transplantation, allergy and asthma. They are also used as antithrombotic drugs. The role of monoclonal antibodies is, however, limited by expense, the requirement for parenteral administration and concerns about new adverse effects.
Nomenclature
Monoclonal antibodies are created by a single clone of antibody-producing cells so they share the same unique antigen target. Although initially produced using hybridoma technology, recombinant techniques are now used.
The names of monoclonal antibodies use a suffix to characterise the structure and method of production ( Table 1 ). The most recent products are wholly human molecules generated by recombinant techniques and carry the suffix '-umab'.
Mechanisms of action
The effectiveness of monoclonal antibodies is dependent on:
■ the function and characteristics of the target antigen ■ the cell surface density or tissue distribution of the antigen ■ factors associated with the monoclonal antibody itself (specificity, avidity and isotype).
Monoclonal antibodies work by a number of mechanisms such as blocking the function of the target molecule, inducing the death of cells that express the target, or by modulating signalling pathways. 2 These actions have been exploited in a range of proven and experimental indications ( 
Inhibition of tumour necrosis factor

Inhibition of lymphocyte traffic
Multiple sclerosis is likely to be an immune-mediated demyelination in the central nervous system. The migration of activated T cells into the brain and spinal cord is thought conditions has yet to be fully explored.
Preventing organ rejection
B cell depletion
Rituximab is a monoclonal antibody that targets a molecule 
Use in skin disorders
The pathogenesis of psoriasis involves a number of immune mechanisms including the activation of T lymphocytes and the release of inflammatory cytokines such as TNF. 8 Inhibitors of TNF can induce an improvement in many patients with moderate to severe plaque psoriasis. For example, a placebo-controlled trial of infliximab infusions showed that after 50 weeks 61% of patients had a 75% improvement in their psoriasis. 9 This response may be sustained following treatment cessation.
Efalizumab is a monoclonal antibody that targets part of the lymphocyte function-associated antigen-1 (LFA-1) on T cells.
This antigen has roles in both T cell activation and migration so binding to it can improve moderate to severe psoriasis. 
Use in preventing thrombosis
Use in allergic diseases
Immunoglobulin E (IgE) is a pivotal antibody in the allergic response. When allergen-specific IgE on the surface of mast cells 
Limitations of monoclonal antibody therapy
Monoclonal antibody therapies are not used more widely because of: 
Adverse effects
Monoclonal antibodies have to be administered parenterally.
The costs of cannulation and injection site reactions may be considerable.
New and unexpected serious adverse effects are emerging. 
Anti
